Revolutionizing Alzheimer’s Research: Neuronascent Unveils Groundbreaking Parkinson’s Model Data at AAIC 2023 for NNI-362 Investigational Therapy
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) — Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted…